LSTA

#4144
Lisata Therapeutics, Inc. - Common Stock
3.2 5 USD
-1.81%
부문: 헬스케어
베이스: USD
수익 통화: USD
일일 변동 비율
3.25
3.25
년간 변동
1.81
5.06
일일 변동
-1.81%
월간 변동
+1.25%
6달 변화
+58.54%
년간 변동율
+16.49%
이전 종가
3.3 1
Open
3.2 5
저가
3.2 5
High
3.2 5
양
4
전체 차트 열기 Full chart

Financials

개요 성명 통계
4분기 연간
  • Market Capitalization 29.6 M
  • Employee 21
  • Founded 1980
  • CEO N/A
  • Website www.lisata.com
  • Headquarter Delaware, United States
  • FIGI BBG000BNVDR4
  • Industry 생명공학
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
-0.97
주가매출액비율
95.05

Lisata Therapeutics, Inc. - Common Stock

Lisata Therapeutics is an American clinical stage pharmaceutical company active in the field of oncology, specifically aimed at developing and commercializing new cancer therapies. It was formed through a merger of Cend Therapeutics and Caladrius Biosciences in September 2022. In 2019, the FDA granted their product, certepetide, orphan drug status in pancreatic cancer, followed by a Fast track status in 2022. Non-clinical data collected by Lisata and others have demonstrated enhanced delivery of various existing and emerging anti-cancer therapies, including chemotherapies, immunotherapies and RNA-based therapeutics when used with certepetide.

뉴스